1. Главная
  2. Ресурсы
  3. Библиотечный поиск
Pseudoprogression ofGlioblastoma afterChemo- and RadiationTherapy: Diagnosis byUsing DynamicSusceptibility-weighted Contrast-enhancedPerfusion MR… Seymur GahramanovLeslie L. MuldoonCsanád Várallyay2012 год

Pseudoprogression of Glioblastoma after Chemo- and Radiation Therapy: Diagnosis by Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging with Ferumoxytol versus Gadoteridol and Correlation with Survival
статья из журнала

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: Purpose To compare gadoteridol and ferumoxytol for measurement of relative cerebral blood volume (rCBV) in patients with glioblastoma multiforme (GBM) who showed progressive disease at conventional magnetic resonance (MR) imaging after chemo- and radiation therapy (hereafter, chemoradiotherapy) and to correlate rCBV with survival. Materials and Methods Informed consent was obtained from all participants before enrollment in one of four institutional review board–approved protocols. Contrast agent leakage maps and rCBV were derived from perfusion MR imaging with gadoteridol and ferumoxytol in 19 patients with apparently progressive GBM on conventional MR images after chemoradiotherapy. Patients were classified as having high rCBV (>1.75), indicating tumor, and low rCBV (≤1.75), indicating pseudoprogression, for each contrast agent separately, and with or without contrast agent leakage correction for imaging with gadoteridol. Statistical analysis was performed by using Kaplan-Meier survival plots with the log-rank test and Cox proportional hazards models. Results With ferumoxytol, rCBV was low in nine (47%) patients, with median overall survival (mOS) of 591 days, and high rCBV in 10 (53%) patients, with mOS of 163 days. A hazard ratio of 0.098 (P = .004) indicated significantly improved survival. With gadoteridol, rCBV was low in 14 (74%) patients, with mOS of 474 days, and high in five (26%), with mOS of 156 days and a nonsignificant hazard ratio of 0.339 (P = .093). Five patients with mismatched high rCBV with ferumoxytol and low rCBV with gadoteridol had an mOS of 171 days. When leakage correction was applied, rCBV with gadoteridol was significantly associated with survival (hazard ratio, 0.12; P = .003). Conclusion Ferumoxytol as a blood pool agent facilitates differentiation between tumor progression and pseudoprogression, appears to be a good prognostic biomarker, and unlike gadoteridol, does not require contrast agent leakage correction. © RSNA, 2012
Год издания: 2012
Авторы: Seymur Gahramanov, Leslie L. Muldoon, Csanád Várallyay, Xin Li, Dale F. Kraemer, Rongwei Fu, Bronwyn E. Hamilton, William D. Rooney, Edward A. Neuwelt
Издательство: Radiological Society of North America
Источник: Radiology
Ключевые слова: MRI in cancer diagnosis, Glioma Diagnosis and Treatment, Advanced MRI Techniques and Applications
Другие ссылки: Radiology (HTML)
Europe PMC (PubMed Central) (PDF)
Europe PMC (PubMed Central) (HTML)
PubMed Central (HTML)
PubMed (HTML)